Premium
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age
Author(s) -
Gesche Jens,
Beckert Stefan,
Neunhoeffer Felix,
Kachanov Denis,
Königsrainer Alfred,
Seitz Guido,
Fuchs Jörg
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27517
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , cytoreductive surgery , rhabdomyosarcoma , intraperitoneal chemotherapy , cisplatin , chemotherapy , surgery , doxorubicin , blood cancer , sarcoma , cancer , pathology , ovarian cancer
Advanced and relapsed intraperitoneal rhabdomyosarcomas in young children represent an oncological challenge and options for local tumor control are limited. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is commonly used in advanced peritoneal tumors in adults. However, no studies are available regarding CRS and HIPEC in young children. We report our experiences treating six patients with intraperitoneal rhabdomyosarcoma with CRS and HIPEC using cisplatin and doxorubicin focusing on safety and outcomes. No procedure‐associated mortalities occurred and no major short‐ or long‐term toxicities were recorded. All patients showed no evidence of disease after 12‐month median (7–41) follow‐up.